Thomas Gunderson Quotations

The price that I think you'd have to pay for St. Jude would be even more expensive than what Guidant is being bid for today.

He is an extraordinary manager and leader of St. Jude, and he is in the right job for him. You need to be independent, hard-driving and be your own person. You're small and playing the rules close to the edge. That's not the J&J way.

I think Jim Tobin is a great captain of the ship.

I think it's brilliant. The worst-case outcome for them is that they delay Johnson and force them to pay several million dollars more for Guidant, which weakens them as a competitor.

Tobin being here full time is good ? you want someone with authority on site. That will make decision-making a lot faster.

Wall Street did not have a good feeling for what's next for Boston Scientific.

Each would like to keep the other from having Guidant.

Another company could have been in that situation and not have been able to take advantage of the situation. They were ready to have good luck.

We all knew the lawsuits were coming. If J&J walks away from this deal, it'll be because of money, not because they're surprised by something in these documents.

Boston Scientific has always been impressive -- they've done so many acquisitions over the years. They have a SWAT team that is just at its peak -- they come in and say hey, we're going to do a deal, and boom.

The thing that's keeping this tennis match going longer is that both sides, if they can't have it, they really don't want the other guy to have it.

That (smaller market share) was expected. What wasn't expected is that the overall market is smaller than anticipated.

Q4 is behind us, and what the Boston Scientific investment thesis is now is the future, and particularly the future with Guidant.

There's kind of an axiom out there that when Larry Best buys you should buy and when Larry Best sells you should sell.

This is not one of those situations. This is just a difficult time the company will work itself through.

In my experience, these investigations can take years and generally don't have any immediate influence on the fundamentals of the companies.

I'm leaning toward J&J not increasing their bid and essentially taking a walk, but it's close.

St. Jude has a very rich stock price right now.

They are more bullish about their ability to pay down their debt than Wall Street had expected.

They are not for sale, they are not looking to be for sale and they are happy doing what they are doing which is adding new products and growing like a weed.

If there is a bidding war, the last bid may be the 'losing bid' because that will be the amount that is outlandishly excessive and the 'winner' will have to live with their too-highly priced acquisition.

Arden Hills is what's providing the cash flow right now.

The irony is, J&J could have had this company for $76 a share.

A combination of new product launches, contract selling, Guidant missteps, and a favorable market dynamic have increased St. Jude's overall worldwide market share.

They fell a little short of our aggressive ICD numbers.

We will see more battles of the data.

It's a pretty complex juggling act. It adds a level of risk we haven't seen before.

There will be a lot of noise and statistics and science in their battle for market share, but in the end, I doubt things will change much.